PPT1 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P50897 |
---|---|
Clone Names | 100617087 |
Gene ID | 5538 |
---|---|
Other Names | Palmitoyl-protein thioesterase 1, PPT-1, Palmitoyl-protein hydrolase 1, PPT1, PPT |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | PPT1 |
---|---|
Synonyms | CLN1 {ECO:0000303|PubMed:19941651}, PPT |
Function | Removes thioester-linked fatty acyl groups such as palmitate from modified cysteine residues in proteins or peptides during lysosomal degradation. Prefers acyl chain lengths of 14 to 18 carbons (PubMed:8816748). |
Cellular Location | Lysosome. Secreted {ECO:0000250|UniProtKB:P45478} |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene is a small glycoproteininvolved in the catabolism of lipid-modified proteins duringlysosomal degradation. The encoded enzyme removes thioester-linkedfatty acyl groups such as palmitate from cysteine residues. Defectsin this gene are a cause of infantile neuronal ceroidlipofuscinosis 1 (CLN1, or INCL) and neuronal ceroid lipofuscinosis4 (CLN4). Two transcript variants encoding different isoforms havebeen found for this gene.
References
Ohno, K., et al. Brain Dev. 32(7):524-530(2010)Simonati, A., et al. Pediatr. Neurol. 40(4):271-276(2009)Martins-de-Souza, D., et al. Eur Arch Psychiatry Clin Neurosci 259(3):151-163(2009)Kousi, M., et al. Brain 132 (PT 3), 810-819 (2009) :Gregorio, S.P., et al. Psychiatry Res 165 (1-2), 1-9 (2009) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.